Literature DB >> 25982207

Updates on Aspergillus, Pneumocystis and other opportunistic pulmonary mycoses.

Jose Curbelo1, Jose María Galván1, Javier Aspa2.   

Abstract

Mycoses are serious diseases with potentially fatal outcome. The introduction of immunosuppressive treatments and life support techniques has led to a growing prevalence of different degrees of immunosuppression. Compromised immune response is the primary risk factor for the development of opportunistic mycoses. Early diagnosis and treatment are crucial for improving prognosis. However, isolation in cultures or identification using antigen detection techniques cannot distinguish between colonization and invasive infection, and the clinical status of the patient often prevents biopsy sampling. Clinicians thus find themselves in an uncertain position, requiring them to quickly recognize clinical and radiological signs and interpret microbiological results in context. The aim of this review is to provide a general overview of the profile of patients susceptible to these infections, the role of the immune system and, in more detail, the major diagnostic developments that have gained most acceptance and recognition among the scientific community.
Copyright © 2014 SEPAR. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Aspergillus; Aspergilosis pulmonar invasiva; Cryptococcus; Invasive pulmonary aspergillosis; Micosis pulmonares oportunistas; Mucormicosis; Mucormycosis; Opportunistic pulmonary mycoses; Pneumocystis jirovecii

Mesh:

Year:  2015        PMID: 25982207     DOI: 10.1016/j.arbres.2015.02.010

Source DB:  PubMed          Journal:  Arch Bronconeumol        ISSN: 0300-2896            Impact factor:   4.872


  1 in total

1.  Galactomannan use in clinical practice: providing free testing is not the full answer.

Authors:  Jeniffer S Dos Santos; Djuli M Hermes; Alessandro C Pasqualotto
Journal:  Braz J Infect Dis       Date:  2017-11-22       Impact factor: 3.257

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.